BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF).

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it will be presenting at the Canaccord Genuity 40th Annual Growth Conference being held virtually on August 11-13, 2020.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today issued a letter to shareholders discussing the Company’s recent accomplishments and voting recommendations from its Board of Directors for two proposals that are scheduled for shareholder vote on September 3, 2020.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has signed a three-year non-exclusive research agreement with GDM (“GDM”), a company specialized in plant genetics based in Gibson City, Illinois to evaluate novel yield traits in soybean. Under the agreement, GDM plans to work with Yield10 yield traits within its research and development program for soybean as a strategy t

New Drug Application (NDA) for relugolix monotherapy tablet in advanced prostate cancer accepted for Priority Review by the FDA with target action date of December 20, 2020 NDA for relugolix combination tablet in uterine fibroids submitted in May 2020 Additional USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma and commercial collaboration agreement with Sunovion Pharmaceuticals increases financial flexibility and provides access to well-establis

PainTEQ, a leading medical device innovator, launched a first of its kind biomechanical study this month that explores the treatment of sacroiliac (SI) joint pain through a minimally invasive outpatient procedure using a posterior approach.

Company Plans to File Q2 2020 10-Q on August 13, 2020 Save the Date: Company to host virtual disease awareness event on October 20, 2020 focused on cancer therapy-related diarrhea

Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study in Dermatologic Surgery - The SAKURA 3 safety and efficacy results are consistent with those observed in SAKURA 1 and SAKURA 2 studies for DaxibotulinumtoxinA for Injection in the treatment of glabellar (frown) lines – NEWARK, Calif.--( BUSINESS WIRE )-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company fo

First participant dosed in Phase 1 study of SAB-185 for COVID-19 in healthy volunteers Phase 1b clinical trial evaluating the safety and pharmacological activity of SAB-185 in COVID-19 patients slated to start mid-August Novel proprietary technology platform leverages the native human immune response offering a differentiated high-potency therapeutic option to address virus mutations amidst ongoing pandemic

A chorus of expert female voices, including caucus co-chairs Reps. Brenda Lawrence, Debbie Lesko, Vice-Chair Madeleine Dean, and Jedediah Bila of Fox & Friends Weekend to tackle growing concerns